Actinium Initiates Second Dosing Cohort of Novel Combination Trial with Actimab-A and CLAG-M Salvage Regimen at Medical College of Wisconsin Feb 4, 2019
Actinium Pharmaceuticals to Host Key Opinion Leader Breakfast on Targeted Conditioning for Bone Marrow Transplant and CAR-T on February 7th Jan 29, 2019
Actinium Pharmaceuticals, Inc. to Present at Noble Capital Markets' 15th Annual Investor Conference Jan 25, 2019
Actinium Pharmaceuticals Appoints Accomplished Industry Executive Cynthia Pussinen as Executive Vice President of Technical Operations and Supply Chain Jan 23, 2019
Actinium Successfully Completes First Module of Collaborative Research Program with Astellas; Second Module Initiated Jan 17, 2019
Actinium Pharmaceuticals Appoints Qing Liang, PhD, DABR as Vice President, Head of Radiation Sciences to Further Innovation for its AWE Technology Platform and Growing Pipeline of Antibody Radiation Conjugate Therapies Jan 16, 2019
Actinium Pharmaceuticals, Inc. to Present at the 2019 Biotech Showcase™ in San Francisco Jan 3, 2019
Actinium Pharmaceuticals Highlights Analysis of Pivotal Iomab-B Phase 3 SIERRA Trial Presented in Oral Session at ASH Annual Meeting Dec 4, 2018
Actinium Highlights Actimab-A Phase 2 Trial Results in Older Patients with Unfit AML from ASH Annual Meeting Demonstrating Single Agent Activity of the CD33 Antibody Radiation Conjugate Dec 3, 2018
